News Releases

March 19, 2018
Synlogic to Present Data at the American Association for Cancer Research 2018 Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 19, 2018-- Synlogic, Inc. , (Nasdaq: SYBX ) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that preclinical data from its immuno-oncology (IO) program will...
March 12, 2018
Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic Disorders
– Expanded clinical data set from Phase 1 study confirms proof of mechanism and supports continued development of SYNB1020 for treatment of hyperammonemia – – A Phase 1b / 2a clinical trial to further evaluate SYNB1020 is open and screening patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar....
March 5, 2018
Synlogic to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Synlogic (Nasdaq:SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present a corporate update at the Cowen and Company 38th Annual Health Care Conference at 3:30 p.m....
February 13, 2018
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic™ Medicine
- Data presented at Keystone Symposium demonstrate rapid tumor rejection in preclinical models - - Data support advancement of Synthetic Biotic medicines as potential immuno-therapies for cancer - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2018-- Synlogic ( Nasdaq: SYBX ), a clinical-stage...
February 8, 2018
Synlogic to Present at the Leerink Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2018-- Synlogic (Nasdaq:SYBX) announced today that its chief medical officer, Aoife Brennan , M.B., B.Ch., and chief financial officer, Todd Shegog will present a corporate update at the Leerink Partners 7th Annual Global Healthcare Conference at 3:00...
January 31, 2018
Synlogic Announces Underwriters’ Option Exercise in Full
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2018-- Synlogic (Nasdaq: SYBX) , a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced it has issued an additional 769,500 shares of common stock at the public offering price of $9.75 per...
January 24, 2018
Synlogic Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- Synlogic (Nasdaq: SYBX) a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced the pricing of its underwritten public offering of 5,130,000 shares of its common stock at a public...
January 23, 2018
Synlogic Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2018-- Synlogic (Nasdaq: SYBX) a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has commenced an underwritten public offering of its common stock....
January 5, 2018
Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2018 Catalysts
– Presentation of full clinical data from first in-human study of Synthetic Biotic™ medicine expected in 1Q 2018 – – IND for SYNB1020 for the treatment of hyperammonemia in patients with liver disease has been cleared by the FDA – – Additional trials in patients with UCD and PKU expected to begin...
December 8, 2017
Synlogic and Ginkgo Bioworks Announce Collaboration as First Step Toward Building an Unprecedented Discovery Engine for Novel Living Medicines in Neurological and Liver Disorders
Partnership Integrates Living Medicine Drug Discovery and Development Expertise with Leading Industrial-Scale Organism Engineering Applied to Therapeutics for the First Time Companies Aim to Expand Portfolio of Novel, Probiotic-Based, Living Medicines with Additional Partners BOSTON & CAMBRIDGE,...
November 13, 2017
Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress
- Reported Positive Top-line Results from Phase 1 Clinical Study of SYNB1020 in Healthy Volunteers - - Received Orphan Drug Designation for SYNB1618, a Synthetic Biotic TM Medicine for the Treatment of Phenylketonuria - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 13, 2017-- Synlogic, Inc....
November 8, 2017
Synlogic to Present at Upcoming Investor Conferences in November
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present at the following conferences in November: The Stifel 2017 Healthcare Conference at 11:45 am ET on November 15 th...
Displaying 97 - 108 of 136